Oral vaccination: where we are?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Opinion on Drug Delivery

• Publication date

  2007-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/17425247.4.4.323PMID 17683247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EVALUATION OF ORAL AND SUBCUTANEOUS DELIVERY OF AN EXPERIMENTAL CANARYPOX RECOMBINANT CANINE DISTEMPER VACCINE IN THE SIBERIAN POLECAT (MUSTELA EVERSMANNI)

  2009cited by this paper
• Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm.

  2007cited by this paper
• Enhanced immune responses induced by vaccine using Sendai virosomes as carrier.

  2007cited by this paper
• Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants.

  2007cited by this paper
• Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.

  2007cited by this paper
• Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

  2007cited by this paper
• Immunity development following oral vaccination against Actinobacillus pleuropneumoniae in a mouse model

  2007cited by this paper
• Production of Escherichia coli heat labile toxin (LT) B subunit in soybean seed and analysis of its immunogenicity as an oral vaccine.

  2007cited by this paper
• Protection of Procambarus clarkii against white spot syndrome virus using recombinant oral vaccine expressed in Pichia pastoris.

  2007cited by this paper
• Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909.

  2007cited by this paper
• Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant.

  2006cited by this paper
• Nasal Vaccination With CpG Oligodeoxynucleotide Induces Protective Immunity Against Nontypeable Haemophilus influenzae in the Nasopharynx

  2006cited by this paper
• Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.

  2006cited by this paper
• Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.

  2006cited by this paper
• A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2.

  2006cited by this paper
• A Bacterial Flagellin, Vibrio vulnificus FlaB, Has a Strong Mucosal Adjuvant Activity To Induce Protective Immunity

  2006cited by this paper
• Safety and Efficacy of Nasal Application of CpG Oligodeoxynucleotide as a Mucosal Adjuvant

  2006cited by this paper
• Dukoral®, vaccin roal contre le choléra

  2006cited by this paper
• Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus.

  2006cited by this paper
• Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity.

  2006cited by this paper
• Crude saponins improve the immune response to an oral plant-made measles vaccine.

  2006cited by this paper
• Mucosal Adjuvant Properties of the Shigella Invasin Complex

  2006cited by this paper
• The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis

  2006cited by this paper
• Oral immunogenicity of a plant-made, subunit, tuberculosis vaccine.

  2006cited by this paper
• Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers

  2006cited by this paper
• Bacillus anthracis Edema Toxin Acts as an Adjuvant for Mucosal Immune Responses to Nasally Administered Vaccine Antigens1

  2006cited by this paper
• Oral immunisation of laying hens with the live vaccine strains of TAD Salmonella vac E and TAD Salmonella vac T reduces internal egg contamination with Salmonella Enteritidis.

  2006cited by this paper
• Vaginal Protection and Immunity after Oral Immunization of Mice with a Novel Vaccine Strain of Listeria monocytogenes Expressing Human Immunodeficiency Virus Type 1 gag

  2006cited by this paper
• Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria.

  2006cited by this paper
• Characterisation of the oral adjuvant effect of lemnan, a pectic polysaccharide of Lemna minor L.

  2006cited by this paper
• Application of the Arming System for the Expression of the 380R Antigen from Red Sea Bream Iridovirus (RSIV) on the Surface of Yeast Cells: A First Step for the Development of an Oral Vaccine

  2006cited by this paper
• Nasal Immunization with Anthrax Protective Antigen Protein Adjuvanted with Polyriboinosinic–Polyribocytidylic Acid Induced Strong Mucosal and Systemic Immunities

  2006cited by this paper
• Levamisole synergizes experimental F4ac+ Escherichia coli oral vaccine in stimulating ileal Peyer's patch T cells in weaned pigs.

  2006cited by this paper
• Use of an oral diphtheria vaccine in human.

  2006cited by this paper
• Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant.

  2006cited by this paper
• Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.

  2006cited by this paper
• An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express α-fetoprotein

  2006cited by this paper
• Mucosal Administration of CpG Oligodeoxynucleotide Elicits Strong CC and CXC Chemokine Responses in the Vagina and Serves as a Potent Th1-Tilting Adjuvant for Recombinant gD2 Protein Vaccination against Genital Herpes

  2006cited by this paper
• Salmonella enterica serovar Choleraesuis infection of the porcine jejunal Peyer's patch rapidly induces IL-1beta and IL-8 expression.

  2006cited by this paper
• 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.

  2006cited by this paper
• Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

  2006cited by this paper
• Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses

  2006cited by this paper
• DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus.

  2006cited by this paper
• Mannosylated Niosomes as Adjuvant-Carrier System for Oral Mucosal Immunization

  2006cited by this paper
• Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa.

  2006cited by this paper
• Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media.

  2006cited by this paper
• TLR4 agonists as immunomodulatory agents

  2006cited by this paper
• A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.

  2006cited by this paper
• Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus).

  2006cited by this paper
• Capric Acid and Hydroxypropylmethylcellulose Increase the Immunogenicity of Nasally Administered Peptide Vaccines

  2006cited by this paper
• Optimized FaeG Expression and a Thermolabile Enterotoxin DNA Adjuvant Enhance Priming of an Intestinal Immune Response by an FaeG DNA Vaccine in Pigs

  2006cited by this paper
• Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles.

  2006cited by this paper
• A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype.

  2006cited by this paper
• Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer

  2006cited by this paper
• Clinical and Microbiological Responses of Volunteers to Combined Intranasal and Oral Inoculation with a Streptococcus gordonii Carrier Strain Intended for Future Use as a Group A Streptococcus Vaccine

  2005cited by this paper
• Oral infection with the Salmonella enterica serovar Gallinarum 9R attenuated live vaccine as a model to characterise immunity to fowl typhoid in the chicken

  2005cited by this paper
• BMC Veterinary Research BioMed Central

  2005cited by this paper
• Macrophage inflammatory protein-1alpha expression plasmid enhances DNA vaccine-induced immune responses against HSV-2.

  2005cited by this paper
• Bacterial Ghosts as an Oral Vaccine: a Single Dose of Escherichia coli O157:H7 Bacterial Ghosts Protects Mice against Lethal Challenge

  2005cited by this paper
• [Preparation oral liposome-encapsulated recombinant Helicobacter pylori heat shock protein 60 vaccine for prevention of Hp infection].

  2005cited by this paper
• A Novel Mucosal Vaccine Against Foot-and-Mouth Disease Virus Induces Protection in Mice and Swine

  2005cited by this paper
• Expression of cholera toxin B subunit and assembly as functional oligomers in silkworm.

  2005cited by this paper
• Immune-Reconstituted Influenza Virosome Containing CD40L Gene Enhances the Immunological and Protective Activity of a Carcinoembryonic Antigen Anticancer Vaccine

  2005cited by this paper
• Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization

  2005cited by this paper
• A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice.

  2005cited by this paper
• Exploiting receptor biology for oral vaccination with biodegradable particulates.

  2005cited by this paper
• Evaluation of the Lon‐Deficient Salmonella Strain as an Oral Vaccine Candidate

  2005cited by this paper
• A human papillomavirus type 16 vaccine by oral delivery of L1 protein.

  2005cited by this paper
• Macrophage inflammatory protein‐1α expression plasmid enhances DNA vaccine‐induced immune responses against HSV‐2

  2005cited by this paper
• Cell surface display system for Lactococcus lactis: a novel development for oral vaccine

  2005cited by this paper
• A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses.

  2005influential reference
• Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer.

  2005cited by this paper
• Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii

  2005cited by this paper
• Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in healthy toddlers and children in Chile

  2004cited by this paper
• Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV.

  2004influential reference
• Efficient delivery of DNA to dendritic cells mediated by influenza virosomes.

  2004cited by this paper
• Virosome and ISCOM vaccines against Newcastle disease: preparation, characterization and immunogenicity.

  2004cited by this paper
• Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand

  2004cited by this paper
• Use of a Clostridium perfringens vector to express high levels of SIV p27 protein for the development of an oral SIV vaccine.

  2004cited by this paper
• Secretory Immunoglobulin A Antibodies against the σ1 Outer Capsid Protein of Reovirus Type 1 Lang Prevent Infection of Mouse Peyer's Patches

  2004cited by this paper
• Utilizing Bacterial Mechanisms of Epithelial Cell Entry: Invasin-induced Oral Uptake of Latex Nanoparticles

  2004cited by this paper
• Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization.

  2004cited by this paper
• Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease

  2004cited by this paper
• Development of an anti‐IL‐12 p40 auto‐vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection

  2004cited by this paper
• DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration

  2004cited by this paper
• Enhancement of ovalbumin-specific IgA responses via oral boosting with antigen co-administered with an aqueous Solanum torvum extract.

  2004cited by this paper
• Development of a Virosome Vaccine Against Avian Metapneumovirus Subtype C for Protection in Turkeys

  2004cited by this paper
• Induction of a Mucosal Immune Response to the Streptococcal M Protein by Intramuscular Administration of a PADRE‐ASREAK Peptide

  2004cited by this paper
• Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat.

  2004cited by this paper
• [Incorporation of glycoproteins of the Aujeszky's disease virus ( Suid herpesvirus 1) into artificial liposome membranes and their interaction with cells].

  2004cited by this paper
• [Inhibition of replication of Venezuelan equine encephalomyelitis with polyclonal antibodies to laminin-binding protein].

  2004cited by this paper
• Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration.

  2004cited by this paper
• Preparation of Virosomes Coated with the Vesicular Stomatitis Virus Glycoprotein as Efficient Gene Transfer Vehicles for Animal Cells

  2004cited by this paper
• Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.

  2004cited by this paper
• A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine

  2004cited by this paper
• Synthesis and assembly of SIVmac Gag p27 capsid protein cholera toxin B subunit fusion protein in transgenic potato

  2004cited by this paper
• Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes

  2004cited by this paper
• The viral sigma1 protein and glycoconjugates containing alpha2-3-linked sialic acid are involved in type 1 reovirus adherence to M cell apical surfaces.

  2003cited by this paper
• Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis.

  2003cited by this paper
• [Effect of exogenous epitopes of helper T lymphocyte on humoral immunity of HBV S gene DNA immunity].

  2003cited by this paper

• Orally Dissolving Film-Based Influenza Vaccines Confer Superior Protection Compared to the Oral Administration of Inactivated Influenza Virus

  2025cites this paper
• Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures

  2024cites this paper
• Oral administration of recombinant outer membrane protein A-based nanovaccine affords protection against Aeromonas hydrophila in zebrafish

  2024cites this paper
• Bordetella bronchiseptica and Bordetella pertussis: Similarities and Differences in Infection, Immuno-Modulation, and Vaccine Considerations

  2023cites this paper
• Plant-based vaccines and cancer therapy: Where are we now and where are we going?

  2021cites this paper
• Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy

  2021cites this paper
• pH-Controlled Release of Antigens Using Mesoporous Silica Nanoparticles Delivery System for Developing a Fish Oral Vaccine

  2021cites this paper
• COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention

  2021cites this paper
• Advancedoral vaccine delivery strategies for improving the immunity.

  2021cites this paper
• Nanotoxoids: Biomimetic Nanoparticle Vaccines against Infections

  2021cites this paper
• Oral administration of porcine epidemic diarrhea virus spike protein expressing in silkworm pupae failed to elicit immune responses in pigs

  2020cites this paper
• Interim results from ongoing Phase III placebo-controlled, randomized trial of hepcortespenlisimut-L for advanced hepatocellular carcinoma indication

  2020cites this paper
• Advancements in plant transgenomics approach for the biopharmaceutics and vaccines production

  2020cites this paper
• Updated but not outdated "Gliadin": A plant protein in advanced pharmaceutical nanotechnologies.

  2020cites this paper
• Effect of vaccination with a novel GnRH-based immunocontraceptive on immune responses and fertility in rats

  2020cites this paper
• Expression, Purification, And In Vivo Evaluation Of Gfp-Fused M Cell Targeting Receptor Binding Domain Of Protein Fimh.

  2019cites this paper
• Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month

  2019cites this paper
• Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination

  2018cites this paper
• Thermoresponsive Bacteriophage Nanocarrier as a Gene Delivery Vector Targeted to the Gastrointestinal Tract

  2018cites this paper
• Preformulation studies with the Escherichia coli double mutant heat-labile toxin adjuvant for use in an oral vaccine

  2017cites this paper
• Lettuce‐produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination

  2017cites this paper
• Nano-polyplex based on oleoyl-carboxymethy-chitosan (OCMCS) and hyaluronic acid for oral gene vaccine delivery.

  2016cites this paper
• Eyedrop Vaccination Induced Systemic and Mucosal Immunity against Influenza Virus in Ferrets

  2016cites this paper
• Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus.

  2016cites this paper
• Oral exposure to mineral oils: Is there an association with immune perturbation and autoimmunity?

  2016cites this paper
• Controlled and targeted release of antigens by intelligent shell for improving applicability of oral vaccines.

  2016cites this paper
• Chemical Synthesis, Versatile Structures and Functions of Tailorable Adjuvants for Optimizing Oral Vaccination.

  2016cites this paper
• Treatment: Impact of Vaccination and Progress in Vaccine Development

  2015cites this paper
• Novel Role of Intestinal Lipid Transport in Food Allergy and Cholesterol Homeostasis

  2015cites this paper
• Expression and characterization of an M cell-specific ligand-fused dengue virus tetravalent epitope using Saccharomyces cerevisiae.

  2015cites this paper
• Divalent toxoids loaded stable chitosan-glucomannan nanoassemblies for efficient systemic, mucosal and cellular immunostimulatory response following oral administration.

  2015cites this paper
• Tetanus Toxoids Loaded Glucomannosylated Chitosan Based Nanohoming Vaccine Adjuvant with Improved Oral Stability and Immunostimulatory Response

  2014cites this paper
• Flagellin in Fusion with Human Rotavirus Structural Proteins Exerts an Adjuvant Effect When Delivered with Replicating but Non-Disseminating Adenovectors Through the Intrarectal Route

  2014cites this paper
• Concepts in Mucosal Immunity and Mucosal Vaccines

  2014cites this paper
• Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.

  2013cites this paper
• An Investigation into the Use of a Plant-Expressed Virus-Like Particle as an Oral Vaccine Candidate

  2013influential citation
• Prospects for oral replicating adenovirus-vectored vaccines.

  2013cites this paper
• Development of a fast-dissolving tablet formulation of a live attenuated enterotoxigenic E. coli vaccine candidate.

  2013cites this paper
• Fatty acids as therapeutic auxiliaries for oral and parenteral formulations.

  2013cites this paper
• Therapeutic Vaccination of Treatment-Failed TB Patients on âÂÂPalliativeâÂÂSupport Consisting of Isoniazid and Rifampicin

  2013cites this paper
• Routes of Delivery for Biological Drug Products

  2013cites this paper
• Adjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV.

  2012cites this paper
• Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

  2011cites this paper
• Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB.

  2011cites this paper
• Flagellin produced in plants is a potent adjuvant for oral immunization.

  2011cites this paper
• Characterization of Antigenic Determinants in ApxIIA Exotoxin Capable of Inducing Protective Immunity to Actinobacillus pleuropneumoniae Challenge

  2011cites this paper
• Preliminary evidence of safety and efficacy of an orally administered, heat-inactivated H5N1 influenza vaccine

  2010cites this paper
• Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices.

  2010cites this paper
• Alternative approaches to vaccine delivery

  2010cites this paper
• In vitro identification of targeting ligands of human M cells by phage display.

  2010cites this paper
• In vitro identification of targeting ligands of human M cells by phage display

  2010cites this paper
• Impaired functioning of immune defenses to infection in premature and term infants and their implications for vaccination

  2010cites this paper
• Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study

  2010influential citation
• AdjuvantImmunization with Antigen and Mucosal Immune Responses after Mucosal NK Cells Influence Both Innate and Adaptive

  2010cites this paper
• Protection against pneumonic plague following oral immunization with a non-replicating vaccine.

  2010cites this paper
• NK Cells Influence Both Innate and Adaptive Immune Responses after Mucosal Immunization with Antigen and Mucosal Adjuvant

  2010cites this paper
• Evaluation of baits for oral vaccination of European wild boar piglets.

  2009cites this paper
• Mucosal vaccination of the newborn: an unrealized opportunity

  2009cites this paper
• Oral Live Vaccine Strain-Induced Protective Immunity against Pulmonary Francisella tularensis Challenge Is Mediated by CD4+ T Cells and Antibodies, Including Immunoglobulin A

  2009cites this paper
• Strategies in Oral Immunization

  2009cites this paper
• Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination.

  2009cites this paper
• Preclinical models for pulmonary drug delivery

  2009cites this paper
• Clinical experience with therapeutic vaccines designed for patients with hepatitis.

  2009cites this paper
• Mouse models for the study of mucosal vaccination against otitis media.

  2008cites this paper
• "Vaccination" of shrimp against viral pathogens: phenomenology and underlying mechanisms.

  2008cites this paper
• Oral vaccine delivery: can it protect against non-mucosal pathogens?

  2008cites this paper
• Journal of Hepatocellular Carcinoma Dovepress Open-label Phase Ii Clinical Trial in 75 Patients with Advanced Hepatocellular Carcinoma Receiving Daily Dose of Tableted Liver Cancer Vaccine, Hepcortespenlisimut-l

  year unknowncites this paper